The cardiorenal problem by Pollock, Emiliy & Nowak, Albina
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2014
The cardiorenal problem
Pollock, Emiliy; Nowak, Albina
Abstract: Cardiorenal syndrome (CRS) describes the reciprocally detrimental interaction between both
acute and chronic cardiac and renal dysfunction. The syndrome is prevalent and carries a high mortality.
CRS has five clinical subtypes, which share common pathogenetic mechanisms including neurohumoral
and haemodynamic derangements. We describe several serum markers that offer improvements over
traditional measurement of serum creatinine for the diagnosis of CRS. The mainstay of therapy of CRS
is loop diuretics in the acute setting and ACE-inhibition in the chronic setting, the latter should in most
cases continue despite therapy-associated increases in creatinine. Extracorporeal therapies remain second
line treatment.
DOI: 10.4414/smw.2014.14051
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-102114
Published Version
Originally published at:
Pollock, Emiliy; Nowak, Albina (2014). The cardiorenal problem. Swiss Medical Weekly:1-6. DOI:
10.4414/smw.2014.14051
Review article: Current opinion | Published 4 December 2014, doi:10.4414/smw.2014.14051
Cite this as: Swiss Med Wkly. 2014;144:w14051
The cardiorenal problem
Emiliy Pollock, Albina Nowak
Division of Internal Medicine, University Hospital Zurich, Zurich, Switzerland
Summary
Cardiorenal syndrome (CRS) describes the reciprocally
detrimental interaction between both acute and chronic car-
diac and renal dysfunction. The syndrome is prevalent and
carries a high mortality. CRS has five clinical subtypes,
which share common pathogenetic mechanisms including
neurohumoral and haemodynamic derangements. We de-
scribe several serum markers that offer improvements over
traditional measurement of serum creatinine for the dia-
gnosis of CRS. The mainstay of therapy of CRS is loop di-
uretics in the acute setting and ACE-inhibition in the chron-
ic setting, the latter should in most cases continue despite
therapy-associated increases in creatinine. Extracorporeal
therapies remain second line treatment.
Key words: cardiorenal syndrome; renal dysfunction;
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Introduction
Cardiorenal syndrome (CRS) refers to the increasingly re-
cognised reciprocal association between cardiac and renal
dysfunction, whereby injury to one organ directly promotes
deterioration of the other.
The development of classification systems for acute
(RIFLE, AKIN) and chronic (Kidney Disease Outcomes
Abbreviations
ACCF/AHA American College of Cardiology Foundation/American
Heart Association Heart Failure
ACE angiotensin-converting enzyme
AKI acute kidney injury
ANP atrial natriuretic peptide
BNP brain natriuretic peptide
CKD chronic kidney disease
CRS cardiorenal syndrome
FABP liver-type fatty acid binding protein
GFR Glomerular filtration rate
IL interleukin
KIM-1 kidney injury molecule 1
NAG N-acetyl-beta-D-glucosaminidase
NGAL neutrophil gelatinase-associated lipocalin
NT-proANP amino-terminal pro-atrial natriuretic peptide
NT-proBNP amino-terminal pro-brain natriuretic peptide
RAAS renin-angiotensin-aldosterone system
TNF-α tumour necrosis factor alpha
UO urine output
Quality Initiative (KDOQI) stages 1–5) renal dysfunction
has simplified their diagnosis. Within Europe, the prevalen-
ce of both cardiac and renal dysfunction is increasing [1, 2].
Approximately 5% of acute medical admissions are related
to heart failure [3] and among these patients 20% have ren-
al impairment [4]. In chronic cardiac failure, chronic kid-
ney disease (CKD) is the most common co-morbidity [5].
Conversely, cardiovascular causes account for approxim-
ately 40% of deaths in patients with CKD [6]. Combined
cardiac and renal dysfunction in all settings is related to an
extremely high morbidity and mortality [7, 8]. There may
be reluctance among clinicians to fully treat either the car-
diac or renal problem due to concerns of negatively affect-
ing the other [9]. An awareness of the pathogenesis and ef-
fective treatment of CRS is therefore crucial for improving
the prognosis of this large patient group.
Cardiorenal syndrome includes the four subtypes of acute
heart failure behind the syndrome [7]:
1. Hypertensive pulmonary oedema with preserved left
ventricular systolic function
2. Acutely decompensated chronic heart failure
3. Cardiogenic shock
4. Predominant right ventricular failure
Increasing research interest in CRS was consolidated in
2008 with development of a classification system based
on clinical parameters [7] (table 2). In type 1 CRS, acute
cardiac failure results in acute kidney injury (AKI), as
defined using the Risk-Injury-Failure-Loss-End stage renal
disease (RIFLE) criteria presented in table 1 or altern-
atively using the Acute Kidney Injury Network (AKIN)
criteria. The initial cardiac insult may be ischaemic, due
to acute coronary syndrome or cardiac surgery, or non-
ischaemic, for example in the case of valvular pathology
or pulmonary embolism. In type 2 CRS, chronic cardiac
dysfunction causes progressive CKD. In type 3, AKI is
responsible for a rapid deterioration in cardiac function.
Type 4 refers to the contribution of CKD to chronic cardiac
disease, including coronary artery disease, cardiac failure
and arrhythmia. Finally, in type 5 CRS, a primary systemic
problem, most frequently sepsis, is responsible for a sec-
ondary deterioration of cardiac and renal function. The syn-
drome is however characterised by common pathogenetic
mechanisms across the five categories.
In this review, we mainly focus on type 1 CRS.
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Pathophysiology
The cardiovascular risk factors of hypertension, diabetes,
smoking and hypercholesterolaemia are relevant to both
cardiac and renal disease. Affected patients are predisposed
to developing dual organ dysfunction and are further dis-
advantaged by its corresponding increased mortality over
single organ disease. Type 1 cardiorenal syndrome most of-
ten occurs as an acute-on-chronic phenomenon: the most
frequent predisposing factors are a history of chronic renal
or chronic cardiac failure.
Neurohumoral and haemodynamic mechanisms
In type 1 cardiorenal syndrome, impaired left ventricular
function leads to reduced stroke volume and cardiac output,
arterial underfilling and venous congestion. These haemo-
dynamic derangements result in activation of the renin-
angiotensin-aldosterone system (RAAS) and in release of
vasopressin and endothelin-1, which are responsible for
salt and water retention and systemic vasoconstriction. The
action of endogenous vasodilators including natriuretic
peptides and nitric oxide are overwhelmed and oxygen
delivery to the heart and brain is thus mainly preserved.
However, the resulting decrease in cardiac output and renal
vascular constriction lead to reduced renal perfusion and
glomerular filtration rate (GFR) and the increased preload
predisposes to further left ventricular impairment. Activa-
tion of the same pathways occurs during primary or during
resulting secondary renal dysfunction. Thus the distinction
between primary and secondary dysfunction is lost and a
vicious circle develops. The maladaptive nature of the re-
sponse becomes clear with appreciation of the positive im-
pact on mortality of interruption of the RAAS using an-
giotensin converting enzyme (ACE) inhibitors.
Venous congestion with increased central venous pressure
seems particularly important in the development of type 1
CRS. Animal experiments have previously demonstrated
Table 1: RIFLE classification for acute kidney injury (from Cruz et al.
[10]).
Creatinine/GFR criteria Urine output (UO) criteria
Risk Increased creatinine to 1.5 x
or
GFR decrease >25%
UO <0.5 ml/kg/h for 6h
Injury Increased creatinine to 2 x or
GFR decrease >50%
UO <0.5 ml/kg/h for 12h
Failure Increased creatinine to 3 x or
GFR decrease >75% or
Creatinine >4 mg/dl (with
acute increase ≥0.5 mg/dl)
UO <0.3 ml/kg/h for 24h or
Anuria for 12h
Loss Complete loss of renal function for >4 weeks
ESRD End stage renal disease
Table 2: Classification of cardiorenal syndrome [7].
Type
1
Acute heart failure results in acute kidney injury
Type
2
Chronic cardiac dysfunction causes chronic kidney disease
Type
3
Acute deterioration in renal function causes acute cardiac
dysfunction
Type
4
Chronic kidney disease is responsible for cardiac dysfunction
Type
5
A primary systemic disorder causes both cardiac and renal
dysfunction
a direct transmission of increased central venous pressure
to the renal veins and a resulting reversible decrease in
GFR [11]. This is postulated to occur through increased
renal venous pressure leading to a rise in glomerular vas
efferens pressure, and a resulting reduced differential pres-
sure between vas afferens and vas efferens, this differential
pressure being the driving force for glomerular filtration.
Alternatively, reduced renal perfusion pressure may cause
direct hypoxic renal damage.
Less than 2% of acute cardiorenal syndrome can be ac-
counted for by the subset of decompensated heart failure
patients with cardiogenic shock [4]. The development of
type 1 CRS has instead been correlated with acute hy-
pertension at presentation [12]. In a study of 145 patients
presenting with acute decompensated heart failure, no cor-
relation between cardiac index and development of
worsening renal function was found [13]. These results
were mirrored in the ESCAPE study, in which right atrial
pressure, an indicator of venous congestion, was signific-
antly correlated with baseline GFR, whereas cardiac index
was not [14]. The influence of renal venous pressure may
explain the positive influence of diuretic therapy on GFR
seen in some patients.
Contrast nephropathy
The administration of iodinated contrast agents, particu-
larly in the setting of coronary angiography, is a frequent
precipitant of type 1 CRS. Patients in whom baseline renal
function is impaired are most susceptible to the toxic ef-
fects of contrast media, which typically result in a creat-
inine rise 24–48 h post-administration, potentially requir-
ing renal replacement therapy, with resolution within one
week. Contrast-related toxicity is attributed to a combina-
tion of direct cytotoxic damage to tubules, transient tubule
obstruction by precipitated contrast material and hypoxia in
the renal medulla due to disruption of the microcirculation.
Chronic predisposing factors
In addition to the acute changes described above, underly-
ing factors including inflammation, uraemia and anaemia
predispose to the development of type 1 cardiorenal syn-
drome. Furthermore, in chronic cardiac or renal impair-
ment, increased levels of angiotensin II result in a
profibrotic, procoagulatory, atherogenic and arrhythmo-
genic state [15].
Chronic heart and chronic renal failure are associated with
increased levels of the same pro-inflammatory cytokines
including TNF-α, IL-6 and IL-1 [16, 17]. This chronic im-
mune activation is postulated to contribute to myocyte dys-
function [18] and fluid overload [19] and increase oxidat-
ive stress resulting in further cardiac and renal damage.
Increased levels of uraemic toxins and uric acid have been
recognised as a potential source of cardiovascular dys-
function [20]. Uraemic toxins may directly induce cardiac
dysfunction by causing impaired myocyte contractility via
interference with calcium entry into the cytosol, and in-
creasing fibrosis and adverse cardiac remodelling follow-
ing myocardial infarction [21].
Chronic cardiac and renal failure both commonly result in
anaemia, which in turn worsens the prognosis among af-
fected patients [22]. Anaemia is due to a combination of
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factors including chronic immune activation leading to de-
ranged iron metabolism, reduced erythropoiesis caused by
renal dysfunction and dilutional anaemia caused by hyper-
volaemia.
Diagnosis
The most common, traditional and economical test to es-
timate kidney function in the setting of heart failure is the
measurement of serum creatinine level. Indeed, serum cre-
atinine level together with urine output forms the basis of
both the RIFLE and the AKIN consensus definitions of
acute kidney injury. Both classification systems are suitable
for diagnosis of AKI in cardiorenal syndrome and have
been widely adopted [10]. The small molecule creatinine
(molecular weight 113 Da) is endogenously produced by
muscles and excreted by the kidneys. Thus deterioration in
kidney function leads to increased serum creatinine level.
The measurement of creatinine is straightforward and inex-
pensive. However, the limitations of serum creatinine as a
marker are particularly relevant in the setting of cardiorenal
syndrome. In particular, patients with cardiac failure tend
to be of low muscle mass resulting in low creatinine levels,
which can cause overestimation of kidney function. Kid-
ney function estimation equations taking account of age,
sex and race allow only partial correction for this problem
and are not validated in acute renal dysfunction. Further-
more, creatinine is not only filtered in the glomerulus but is
also secreted by the renal tubule. This secretion can main-
tain serum levels within the normal range during the early
stages of reduced clearance by glomerular filtration. Con-
sequently, creatinine is an insensitive marker of renal dys-
function, and changes in its serum concentration often lag
behind when kidney function worsens acutely.
Cystatin C, a 13 kDa housekeeping protein produced by all
nucleated cells, provides several advantages. It offers a ser-
um marker of renal function which is less influenced by
muscle-mass, age and sex, as well as liver disease and in-
flammation. In the physiological state, cystatin C is filtered
at the glomerulus, reabsorbed and almost completely meta-
bolised by renal tubular cells. Even minor changes in renal
function result in a measurable difference in cystatin C ser-
um concentration, and such a difference may be clinically
useful as early as two hours following an acute insult [23].
Similarly, neutrophil gelatinase-associated lipocalin
(NGAL), a 25 kDa polypeptide, is gaining increasing re-
cognition as a marker for AKI. It is expressed by neutro-
phils and epithelial cells and involved in ischemic renal in-
jury and repair processes [24]. It can be measured in blood
and urine. Alvelos et al. recently showed that NGAL can be
considered a potent biomarker in early prediction of CRS
type 1 in patients with acute heart failure [25]. A multi-
centre prospective study evaluating 146 adult patients un-
dergoing scheduled cardiac surgery demonstrated that in-
creased preoperative plasma NGAL was an independent
risk factor for post-cardiac surgery AKI. Moreover, plasma
NGAL showed an earlier peak than serum creatinine, indic-
ating that plasma NGAL can predict the recovery of AKI
earlier [26].
Kidney injury molecule-1 (KIM-1) is a trans-membrane
protein which belongs to the immunoglobulin gene super-
family. It is expressed on the proximal tubule apical mem-
brane cilia of the injured kidney and can be measured in
urine. In a recent study of chronic heart failure, urinary
KIM-1 was increased in heart failure patients compared
with healthy controls, increased significantly with decreas-
ing left ventricular function and severity of New York
Heart Association class and was also a predictor of all-
cause mortality [27]. Furthermore, in 95 patients with acute
kidney injury after cardiac surgery, KIM-1 was a good pre-
dictor for AKI progression.
Natriuretic peptides including brain natriuretic peptide
(BNP) and atrial natriuretic peptide (ANP) are released
during myocardial wall stress and represent a physiological
attempt to counteract the neurohumoral derangements and
hypervolemia seen in cardiorenal syndrome via their role to
increase GFR, sodium and water excretion and vasodilata-
tion. During the secretion of these hormones, their inactive
terminal fragments, N-terminal proBNP (NT-proBNP) and
N-Terminal ANP (NT-proANP), are cleaved in equimolar
relation. The N-terminal parts of these hormones are more
frequently measured due to their better pre-analytic stabil-
ity.
The increased serum levels of natriuretic peptides observed
in renal failure are partly due to reduced renal clearance,
but are also likely to reflect increased production under the
additional haemodynamic strain caused by renal dysfunc-
tion [28]. Natriuretic peptides may thus be thought of as a
combined marker of cardiac and renal dysfunction. Natri-
uretic peptides are of prognostic as well as diagnostic value
in CKD patients. In a cohort of 83 pre-dialysis CKD pa-
tients without clinical heart failure, NT-proBNP levels sig-
nificantly correlated with the combined endpoint of car-
diovascular event or mortality [29] and BNP levels have
additionally been shown to be a mortality predictor in pa-
tients with heart failure [30]. In patients with community-
acquired pneumonia and CRS type 5, natriuretic peptides
were shown to accurately predict an early in-hospital AKI
[31].
Further novel less established biomarkers of CRS are N-
acetyl-beta-D-glucosaminidase (NAG), interleukin-18
(IL-18) and liver-type fatty acid binding protein (FABP).
Treatment
Due to the broad spectrum of CRS, treatment must be
tailored to the individual patient. There are no medical ther-
apies that have been shown to directly improve renal func-
tion in patients with heart failure. Experience with patients
receiving cardiac resynchronisation therapy or intra-aortic
balloon pump has, however, demonstrated the reversible
nature of types 1 and 2 CRS [32, 33]. Improvement of car-
diac function is associated with improved kidney function,
as shown in studies of cardiac resynchronisation therapy
[34], underscoring the importance of cardiorenal interac-
tion.
Treatment in the acute setting
The established pharmacological management here in-
cludes diuretics and vasodilators.
Loop diuretics are the mainstay of therapy, although their
effects on renal function in heart failure patients are vari-
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able and range from decreased GFR, presumably as a con-
sequence of reduced cardiac output, to a potential improve-
ment in GFR which may be mediated by reduced renal
venous pressure or by alleviating right-ventricular-depend-
ent impairment of left ventricular filling. The American
College of Cardiology Foundation/American Heart Associ-
ation Heart Failure (ACCF/AHA) guidelines advise the use
of diuretics to eliminate fluid retention even if this results
in a mild to moderate deterioration in renal function [35].
This approach is based on evidence that intensive diuret-
ic therapy improves survival even in the case of worsen-
ing renal function [36]. However, the optimal dosage and
administration strategy remains unclear: in a prospective,
double-blind, randomised trial involving 308 patients with
acute decompensated heart failure, no difference in patient
symptoms or change in renal function was found when di-
uretic therapy was administered as a bolus as opposed to a
continuous infusion, or at a high as opposed to a low dose
[37].
Serelaxin is a recombinant human relaxin 2 which acts as a
vasodilator promoting increased arterial compliance, cardi-
ac output and renal blood flow [38] and represents an emer-
ging therapy for heart failure. In a randomised placebo-
controlled trial of 1161 patients with acute heart failure
and mild-to-moderate renal dysfunction, Serelaxin resulted
in reduced dyspnoea and 180 day mortality [38]. A sub-
sequent analysis where kidney function was assessed in
more detail revealed a better renal outcome with serelaxin
therapy than placebo: the serelaxin group had significantly
lower serum creatinine and plasma cystatin C values in the
first 5 days after enrolment and, in the case of cystatin C,
serelaxin administration was also associated with a lower
incidence of worsening renal function on day 2. Patients on
serelaxin also had lower levels of blood urea nitrogen and
of uric acid on each of days 1 to 5 after enrolment [39].
The situation for other pharmacological therapies is less
clear. In the acute setting, positive inotropes dobutamin and
dopamine raise cardiac index. A resulting improvement in
renal function has however not been demonstrated. The
situation is similar for calcium-sensitiser levosimendan
[15] and for the phosphodiesterase-inhibitor milrenon [40].
In the ADHERE database, patients treated with vasodilat-
ors and diuretics had a significantly higher rate of worsen-
ing renal function than those treated with diuretics alone,
but this effect could not be separated from patients requir-
ing combination therapy having more severe heart failure
[41].
The use of tolvaptan, a vasopressin 2 receptor antagonist,
aims to inhibit the effects of neurohumoral activation in
CRS. In the EVEREST outcome trial, tolvaptan did not in-
fluence primary endpoints of mortality or heart failure hos-
pitalisation but did lead to an improvement in urine output.
By contrast nesiritide, a recombinant human BNP, was
found not to alter the risk of worsening renal function in
patients with acute decompensated heart failure [42].
The effect of adenosine-antagonist rolofylline was invest-
igated in the PROTECT trial, based on the observation that
adenosine leads to preferential constriction of the afferent
glomerular arteriole and consequent increased tubular so-
dium reabsorption. However, the groups showed no dif-
ference in cardiovascular outcomes or worsening of renal
function, and rolofylline increased the risk of neurological
events [43].
Unfortunately, the occurrence of diuretic resistance, which
refers to persistent signs and symptoms of congestion des-
pite adequate doses of intravenous diuretics, is particularly
prevalent among patients with pre-existing renal impair-
ment. In such patients, extracorporeal therapies may be
indicated for fluid removal. Extracorporeal ultrafiltration
uses a semi-permeable membrane to separate isotonic fluid
from blood. Hereby, water is transported in response to
a trans-membrane pressure gradient. Extracorporeal tech-
niques can be performed intermittently (three times per
week), daily and continuously. Continuous venovenous
haemofiltration or intermittent venovenous haemodialysis
use a synthetic extracorporal membrane and access to the
circulation via a large-lumen catheter. Peritoneal dialysis
uses the peritoneal membrane as the barrier between blood
and ultrafiltrate, and access is achieved through an indwell-
ing transcutaneous catheter inserted into the peritoneal cav-
ity. In order to avoid haemodynamic instability and pre-
serve residual kidney function by slowing fluid removal,
continuous rather than intermittent renal replacement ther-
apy is preferred for decompensated heart failure patients.
Renal replacement therapy has several theoretical advant-
ages over conventional diuretic therapy including con-
trolled removal of isotonic fluid, acidosis correction and
less neurohumoral activation [44]. However, depending on
volume status, ultrafiltration may have positive or negative
effects on neurohormone level and urine output, with pa-
tients with diuresis of less than 1l per day seeming to be-
nefit [45]. The UNLOAD trial demonstrated better restora-
tion of normovolaemia and reduced 90 day hospitalisation
rates in 100 heart failure patients treated with ultrafiltration
rather than conventional diuretics. This sustained benefi-
cial effect of ultrafiltration is thought to be due to recov-
ery of diuretic-responsiveness, which may be related to its
correction of sodium dysbalance [45]. However, the bene-
fits of renal replacement therapy are offset by its increased
invasiveness and risk of AKI, which may then lead to
dialysis-dependence, if excessive or too rapid ultrafiltration
is performed [46]. In CARRESS-HF, a prospective ran-
domised study comparing ultrafiltration or pharmacologic
therapy for patients with heart failure and worsening ren-
al function, there was increased creatinine and rate of ad-
verse events in the ultrafiltration group. Current guidelines
from the ACCF/AHA still recommend renal replacement
therapy as a second-line treatment, particularly in patients
with signs of fluid overload and diuresis of under 1l per 24
hours [47].
Treatment in the chronic setting
The established pharmacological management here in-
cludes ACE-inhibitors, aldosterone-antagonists and beta-
blockers.
ACE-inhibitors antagonise several of the pathways re-
sponsible for CRS: through reduced activation of the
RAAS and production of angiotensin II, they lead to re-
duced adrenaline, noradrenaline and vasopressin levels as
well as decreasing central venous pressure via venodilatory
effects. However, they usually also lead to a small decrease
in GFR mediated by preferential dilatation of the efferent
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glomerular arteriole [48]. In the majority of patients, this
occurs in the first three weeks after starting therapy and
remains stable thereafter [49]. The IMPROVE-HF study
examined the adherence to and effect of guideline-recom-
mended therapies for heart failure in over 34,000 patients
and showed that patients with reduced renal function re-
ceived ACE-inhibitors, angiotensin-receptor blockers
(ARBs) and aldosterone antagonists less frequently than
those with normal renal function [9]. This may have been
due to clinician concerns regarding the decrease in GFR
normally observed after beginning ACE-inhibition.
However, although patients with acute decompensated
heart failure who suffer a decline in renal function have
been observed to have a higher mortality [8], the cause of
decline is important in determining outcome. Analysis of
patients in the SOLVD study group showed that patients
in whom an early decline in renal function occurred after
starting enalapril did not have a higher mortality, whereas
those with worsening renal function in the placebo group
did [49]. Importantly, patients in the enalapril group had a
preserved survival advantage despite reduced GFR. In the
Minnesota Heart Survey, the one-year prognosis of patients
with combined renal and heart failure was significantly im-
proved by prescription of an ACE-inhibitor [50].
Careful consideration is required before initiating treatment
with an ACE-inhibitor in the acute setting as it may induce
acute cardiorenal syndrome in patients with acute salt and
water losses, for example due to acute gastroenteritis. As
ACE-inhibitors are predominantly renally excreted, the
dosage should be adapted according to GFR. By contrast,
ARBs undergo hepatic metabolism. The European Society
of Cardiology advises monitoring with continuation of
therapy when the creatinine level after beginning ACE-in-
hibition does not exceed 266 µmol/l and the serum po-
tassium does not exceed 6 mmol/l. Should these limits be
reached, the benefits of ACE-inhibition are such that stop-
ping other nephrotoxic drugs and halving the dose of ACE-
inhibitor is recommended before stopping the ACE-inhib-
itor outright [51].
Recent trials have supported traditional management of an-
aemia in patients with cardiorenal syndrome using iron
substitution and blood transfusion over prescription of
erythropoietin analogues due to the risk of thromboembolic
adverse effects [52, 53].
Additionally, because of the key role of activation of renal
sympathetic efferent nerves in neurohumoral mechanisms
of CRS, several trials of selective renal denervation in CRS
are ongoing.
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